IFM Therapeutics looks to inhibit STING to treat autoimmune disease 

The Boston firm, which previously developed STING activators for cancer immunotherapy, now plans to tackle the same drug target for different diseases

Source: Chemical and Engineering News - February 11, 2019 Category: Chemistry Authors: Ryan Cross  Source Type: research